Ikena Oncology, Inc. — Q1 2023 Form 10-Q
Entity note: The request metadata names Imagenebio, Inc., but the filing identifies the registrant as Ikena Oncology, Inc. (Nasdaq: IKNA). Confirm that this is the intended filing.
Business context and reporting period
This unaudited quarterly report covers the three months ended March 31, 2023. Ikena is a clinical-stage targeted oncology company with no approved products and no product-sale revenue. Its programs include IK-930, a Hippo-pathway inhibitor in Phase 1; IK-175, an AHR antagonist in a Phase 1a/1b trial and collaboration with Bristol Myers Squibb (BMS); and preclinical candidate IK-595, a MEK-RAF inhibitor.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Collaboration R&D revenue | $5.313 million | $3.384 million |
| Research and development expense | $15.552 million | $14.343 million |
| General and administrative expense | $5.276 million | $6.003 million |
| Total operating expenses | $20.828 million | $20.346 million |
| Loss from operations | $15.515 million | $16.962 million |
| Net loss | $14.219 million | $16.839 million |
| Net loss per share | $0.39 | $0.47 |
| Operating cash used | $19.784 million | $19.784 million |
- Revenue is collaboration revenue, not product sales. The filing reports no product-sale revenue.
- At March 31, cash and cash equivalents were $29.329 million and marketable securities were $108.484 million, totaling $137.813 million in cash, cash equivalents and marketable securities.
- Total assets were $152.401 million; current assets were $141.178 million and current liabilities were $13.950 million. Stockholders’ equity was $135.022 million.
- Total liabilities were $17.379 million, including operating lease liabilities; the filing reports no borrowings or other financial debt.
- Cash, cash equivalents and restricted cash decreased $30.590 million during the quarter. Investing cash outflow was $10.806 million, principally reflecting net purchases of marketable securities.
- No product gross margin is reported. The company remains loss-making, with an accumulated deficit of $228.438 million.
Changes versus the prior comparable period
- Collaboration revenue increased 57%, which the company attributed primarily to redirecting resources toward completing the BMS partnership data package after stopping the IK-175 head-and-neck study before enrollment.
- R&D expense rose 8%, mainly from increased personnel and overhead, partly offset by lower spending on other discovery-stage programs. IK-595 program expense increased 45% to $1.865 million.
- G&A expense declined 12%, mainly due to lower legal, consulting and insurance expenses.
- Net loss narrowed by $2.620 million (16%), reflecting higher collaboration revenue and other income, including interest income of $0.730 million versus $0.172 million a year earlier.
- Cash used in operations was unchanged year over year at $19.784 million. The much smaller investing outflow compared with 2022 primarily reflects the timing of marketable-security purchases.
Outlook, commentary and key risks
- Management estimated that March 31 liquidity would fund operating expenses and capital expenditure requirements into 2025. This is an estimate subject to assumptions; the company expects substantial losses and negative operating cash flows and has no committed external funding source.
- The company plans to submit an IND for IK-595 in the second half of 2023. It expected initial monotherapy IK-930 Phase 1 data in Q4 2023 and said the trial was progressing through dose escalation with no dose-limiting toxicities observed to date.
- IK-175 received FDA fast track designation in March 2023 for use with immune checkpoint inhibitors in a specified advanced urothelial-cancer population. The company planned to provide program updates in 2023. Previously reported combination results included a 40% disease-control rate and 20% overall response rate in urothelial-carcinoma patients; these were initial clinical data, not definitive evidence of efficacy.
- BMS may opt into licenses for IK-175 and IK-412 through early 2024. The filing describes potential option payments of $50 million for IK-175 and $40 million for IK-412, in addition to possible milestones and royalties after license exercise. IK-412 development was paused, apart from committed manufacturing work, following manufacturing delays.
- Principal risks include clinical and regulatory uncertainty, the need for additional capital and potential dilution, reliance on third-party CROs and manufacturers, single-source API suppliers, collaboration-option decisions, and competition. Biomarker-defined patient populations may be small and difficult to enroll.
- The company reported no litigation or legal proceedings that management considered likely to have a material adverse effect. Management concluded disclosure controls were effective at the reasonable assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the filing identity: this report is for Ikena Oncology, Inc., not Imagenebio, Inc.
- Compare actual cash burn and spending with management’s “into 2025” runway estimate, including the timing and cost of planned clinical development.
- Check whether IK-930 data, the IK-595 IND submission, and subsequent program updates occurred on the stated timelines and assess the underlying clinical evidence.
- Track BMS’s option decisions, the status of IK-412, and whether collaboration revenue or potential payments change materially.
- Review future filings for financing activity, ATM sales, dilution, liquidity changes, and any supplier or trial delays.